Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (SHE:000766) — Market Cap & Net Worth
Market Cap & Net Worth: Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (SHE:000766) has a market capitalization of $2.21 Billion (CN¥15.14 Billion) as of September 16, 2026. Listed on the SHE stock exchange, this China-based company holds position #5818 globally and #1082 in its home market, demonstrating a -6.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's stock price CN¥15.66 by its total outstanding shares 966494707 (966.49 Million). Also see how large is Tonghua Golden-Horse Pharmaceutical Indu's balance sheet for a full breakdown of the balance sheet.
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd Market Cap History: 2015 to 2026
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $2.37 Billion to $2.21 Billion (3.55% CAGR). Also see cash flow conversion of Tonghua Golden-Horse Pharmaceutical Indu for how efficiently the company converts equity into cash flow.
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Tonghua Golden-Horse Pharmaceutical Indu stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.32x
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's market cap is 3.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
113.39x
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's market cap is 113.39 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.48 Billion | $850.08 Million | $213.46 Million | 2.92x | 11.63x |
| 2017 | $1.92 Billion | $1.52 Billion | $257.88 Million | 1.26x | 7.46x |
| 2018 | $970.20 Million | $2.09 Billion | $330.86 Million | 0.46x | 2.93x |
| 2019 | $924.94 Million | $1.98 Billion | -$2.04 Billion | 0.47x | N/A |
| 2020 | $461.06 Million | $1.11 Billion | -$359.50 Million | 0.41x | N/A |
| 2021 | $671.79 Million | $1.52 Billion | $35.27 Million | 0.44x | 19.05x |
| 2022 | $745.33 Million | $1.47 Billion | $30.15 Million | 0.51x | 24.72x |
| 2023 | $2.82 Billion | $1.47 Billion | $43.93 Million | 1.91x | 64.19x |
| 2024 | $2.22 Billion | $1.32 Billion | $56.44 Million | 1.68x | 39.34x |
| 2025 | $3.89 Billion | $1.17 Billion | $34.29 Million | 3.32x | 113.39x |
Competitor Companies of 000766 by Market Capitalization
Companies near Tonghua Golden-Horse Pharmaceutical Industry Co Ltd in the global market cap rankings as of September 16, 2026. Review tangible equity quality of Tonghua Golden-Horse Pharmaceutical Indu to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Tonghua Golden-Horse Pharmaceutical Industry Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's market cap moved from $2.37 Billion to $ 2.21 Billion, with a yearly change of 3.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.21 Billion | -43.03% |
| 2025 | CN¥3.89 Billion | +75.10% |
| 2024 | CN¥2.22 Billion | -21.26% |
| 2023 | CN¥2.82 Billion | +278.37% |
| 2022 | CN¥745.33 Million | +10.95% |
| 2021 | CN¥671.79 Million | +45.71% |
| 2020 | CN¥461.06 Million | -50.15% |
| 2019 | CN¥924.94 Million | -4.66% |
| 2018 | CN¥970.20 Million | -49.56% |
| 2017 | CN¥1.92 Billion | -22.55% |
| 2016 | CN¥2.48 Billion | +4.90% |
| 2015 | CN¥2.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.21 Billion USD |
| MoneyControl | $2.21 Billion USD |
| MarketWatch | $2.21 Billion USD |
| marketcap.company | $2.21 Billion USD |
| Reuters | $2.21 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor drugs, gynecological medications, medication for rheumatic bone pain, urological medications, heat-clearing and detoxifying drugs, cardiovascular and cerebrovascular drugs, digestive m… Read more